noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

John W. Hickenlooper

Hickenlooper Statement on Vote to Pay Federal Employees
City of Hoboken, NJ

Hoboken Public Safety Department advances Police Mobile Command Center
Virginia Commonwealth University

Saving the best: Meet VCU field hockey star goalie Emma Clements

Healthcare

Kura Oncology Inc.

10/24/2025 | Press release | Distributed by Public on 10/24/2025 05:25

Material Event (Form 8-K)

Item 8.01

Other Events.

On October 24, 2025, Kura Oncology, Inc. (the "Company") announced receipt of a $30 million milestone payment under its Collaboration and License Agreement with Kyowa Kirin, Inc. and Kyowa Kirin Co., Ltd. (together,"Kyowa Kirin") in connection with the dosing of the first patient in the KOMET-017Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. The Company and Kyowa Kirin announced the launch of the KOMET-017trials on September 29, 2025.

KOMET-017(NCT07007312) comprises two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensivechemotherapy regimens in patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

Kura Oncology Inc. published this content on October 24, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on October 24, 2025 at 11:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]